CA2480099C - Erbb3 based methods and compositions for treating neoplasms - Google Patents

Erbb3 based methods and compositions for treating neoplasms Download PDF

Info

Publication number
CA2480099C
CA2480099C CA2480099A CA2480099A CA2480099C CA 2480099 C CA2480099 C CA 2480099C CA 2480099 A CA2480099 A CA 2480099A CA 2480099 A CA2480099 A CA 2480099A CA 2480099 C CA2480099 C CA 2480099C
Authority
CA
Canada
Prior art keywords
amino acid
protein
seq
peptide
erbb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2480099A
Other languages
English (en)
French (fr)
Other versions
CA2480099A1 (en
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB02116259XA external-priority patent/CN1219882C/zh
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of CA2480099A1 publication Critical patent/CA2480099A1/en
Application granted granted Critical
Publication of CA2480099C publication Critical patent/CA2480099C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2480099A 2002-03-26 2003-03-26 Erbb3 based methods and compositions for treating neoplasms Expired - Fee Related CA2480099C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN02116259.X 2002-03-26
CNB02116259XA CN1219882C (zh) 2002-03-18 2002-03-26 以erbb-3为基础的用于肿瘤治疗的方法和组合物
PCT/CN2003/000217 WO2003080835A1 (en) 2002-03-26 2003-03-26 Erbb3 based methods and compositions for treating neoplasms

Publications (2)

Publication Number Publication Date
CA2480099A1 CA2480099A1 (en) 2003-10-02
CA2480099C true CA2480099C (en) 2019-01-08

Family

ID=28048642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2480099A Expired - Fee Related CA2480099C (en) 2002-03-26 2003-03-26 Erbb3 based methods and compositions for treating neoplasms

Country Status (7)

Country Link
US (2) US7919098B2 (OSRAM)
EP (2) EP2400021B1 (OSRAM)
JP (2) JP4660094B2 (OSRAM)
CN (1) CN100424175C (OSRAM)
AU (1) AU2003218600C1 (OSRAM)
CA (1) CA2480099C (OSRAM)
WO (1) WO2003080835A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
MX2008005640A (es) * 2005-11-02 2008-12-09 Univ Duke Quimioterapia e inmunoterapia concurrentes.
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
BRPI0808055A2 (pt) * 2007-02-16 2013-07-30 Merrimack Pharmaceuticals Inc anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2009157919A1 (en) * 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
AU2009281721A1 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
EP2370093A4 (en) * 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
LT2719708T (lt) 2009-11-13 2018-02-12 Daiichi Sankyo Europe Gmbh Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai
MX2012007340A (es) 2009-12-22 2012-08-01 Roche Glycart Ag Anticuerpos anti/her3 y usos de los mismos.
PL2544680T3 (pl) 2010-03-11 2015-08-31 Merrimack Pharmaceuticals Inc Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
TWI418362B (zh) * 2010-11-19 2013-12-11 Univ Nat Pingtung Sci & Tech 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CA2828043A1 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
US9956276B2 (en) * 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016011343A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Her3 peptides and dendritic cell vaccines
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP2018527286A (ja) * 2015-07-17 2018-09-20 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 免疫に基づく療法のための、免疫原性mhcクラスiiペプチドの同定
US11090284B2 (en) 2015-09-02 2021-08-17 The Cleveland Clinic Foundation Ovarian cancer vaccines
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
CN110167968B (zh) * 2016-09-15 2023-11-28 斯图加特大学 针对her3的抗原结合蛋白
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11890335B2 (en) * 2017-09-27 2024-02-06 L2 Diagnostics, Llc ErbB peptide pharmaceutical and vaccine compositions and therapeutic uses thereof for cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
AU1057097A (en) 1995-12-22 1997-07-17 Beth Israel Deaconess Medical Center Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
EP1728802A3 (en) 1996-03-27 2006-12-13 Genentech, Inc. ErbB3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
EP0938556B1 (en) * 1996-07-12 2005-03-09 Genentech, Inc. Gamma-heregulin
CN100415772C (zh) 1996-10-18 2008-09-03 基因技术股份有限公司 抗ErbB2抗体
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
WO1998035036A1 (en) 1997-02-10 1998-08-13 Genentech, Inc. Heregulin variants
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CA2377665A1 (en) 1999-07-06 2001-01-11 General Atomics Methods and compositions for assaying analytes
CZ20023748A3 (cs) 2000-05-15 2003-04-16 Pharmacia Italia S.P.A. Inhibitory aromatasy a monoklonální anti-HER2 protilátky jako protitumorová činidla
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
BRPI0808055A2 (pt) 2007-02-16 2013-07-30 Merrimack Pharmaceuticals Inc anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo

Also Published As

Publication number Publication date
EP2400021A3 (en) 2012-03-21
AU2003218600C1 (en) 2009-12-17
EP2400021B1 (en) 2016-11-30
US7919098B2 (en) 2011-04-05
CA2480099A1 (en) 2003-10-02
JP2010213710A (ja) 2010-09-30
EP1495123A1 (en) 2005-01-12
JP2005533488A (ja) 2005-11-10
JP4660094B2 (ja) 2011-03-30
CN100424175C (zh) 2008-10-08
US20110229478A1 (en) 2011-09-22
EP1495123B1 (en) 2013-10-30
EP1495123A4 (en) 2009-06-24
EP2400021A2 (en) 2011-12-28
AU2003218600A1 (en) 2003-10-08
WO2003080835A1 (en) 2003-10-02
CN1650011A (zh) 2005-08-03
JP5249282B2 (ja) 2013-07-31
US20080057064A1 (en) 2008-03-06
AU2003218600B2 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
CA2480099C (en) Erbb3 based methods and compositions for treating neoplasms
AU2016201712B2 (en) ActRIIb antagonists and dosing and uses thereof
US11235043B2 (en) Vaccines against antigens involved in therapy resistance and methods of using same
PT1659178E (pt) Processo para a purificação ou produção de uma proteína mage
WO2010105573A1 (zh) 抗血管新生融合蛋白
PT2252627T (pt) Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
JPH01502669A (ja) 精製された血小板由来の成長因子及びその精製方法
JP6576251B2 (ja) PTD−Smad7薬物療法
WO2022100585A1 (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
AU766898B2 (en) Tumor associated antigen 791Tgp72
JP5666110B2 (ja) 高機能化hvj−eの開発
US20080095789A1 (en) Vaccine
KR20090099011A (ko) 암의 치료를 위한 수술, 화학요법 또는 방사선요법과 조합된 면역요법에서 mage a3-단백질 d 융합 항원의 용도
EP4491194A1 (en) Triple combination drug dosing therapy for head and neck cancer treatment
KR20230120543A (ko) c-Met의 에피토프를 포함하는 암 백신 및 이의 용도
KR20200038942A (ko) 약학적 키트 및 그의 용도
HK40084158A (en) Use of antibody-drug conjugate, and combined drug and use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210326